Argenx Reports Positive Phase 3 Results for Vyvgart Hytrulo in Autoimmune Myositis
On August 17, 2026, Argenx announced positive results from its Alkivia Phase 3 trial evaluating Vyvgart Hytrulo (efgartigimod alfa) for adults with autoimmune myositis. The drug showed a statistically significant improvement in the Total Improvement Score at week 52 compared to placebo across both patient subtypes—immune-mediated necrotizing myopathy and dermatomyositis—with notable success observed specifically in IMNM patients. The results highlight Vyvgart Hytrulo's potential as a first-in-class treatment for autoimmune myositis, which affects around 100,000 people in the U.S. with no current targeted therapies available. While the primary endpoint was not met for dermatomyositis due to smaller sample size, clinically meaningful improvements were still observed. Beyond this single trial success, Argenx has a broader pipeline of efgartigimod alfa across multiple autoimmune diseases and is exploring additional therapeutic candidates.
Tickers: $ARGX
Topics: autoimmune_diseases biotech drug_approval